




Lessons learned from immunodeficiency: Understanding how Wiskott-Aldrich syndrome protein (WASp) stings in immune cells



Lisa Westerberg

Karolinska Institutet


Department of Microbiology Tumor and Cell biology

Lisa.Westerberg@ki.se






**Allergy
Autoimmunity
Cancer**



non-self
antigens

self antigens
allergens




**Major infections & Autoimmunity
Allergy
Cancer**

Boy with Wiskott-Aldrich syndrome


Conundrum in Immunology:

How can an immune system fail to respond to non-self pathogens while **reacting vigorously to auto-antigens and allergens?**


The cell cytoskeleton – highly dynamic Regulated by WASp family proteins




Blood circulation



Migration




Cell-to-cell communication



Actin Cytoskeleton




Formin family




WASp family


The actin cytoskeleton



*Podosomes
on dendritic cells*




The actin cytoskeleton



Vaccinia infected macrophage


The actin cytoskeleton




Immunological synapse with *ImageStream* NK cell – Tumor cell

Microscopy




Wildtype NK cells



WASP-/ NK cells



Flow cytometry




Kritikou et al, Scientific Reports 2016


	Count	%Total	%Gated
2295	11.5	100	

The cell cytoskeleton – highly dynamic Regulated by WASp family proteins

WASp family of actin regulators




WASp - regulates the cytoskeleton in immune cells




WASp - A key immunological multitasker


Normal



WAS




XLN




WASp-deficient lymphocytes show abnormal cytoarchitecture

Control




WAS (lack of WASp)




Kenney et al, *Blood* 1986
Molina et al., *Blood* 1997
Westerberg et al., *Blood* 2001, 2005

Lymphocytes expressing overactive WASp show abnormal cytoarchitecture

Control




XLN (overactive WASp)




Moulding et al., *J Exp Med* 2007
Burns et al., *Blood* 2010
Westerberg et al., *J Exp Med* 2010

WASe - A key immunological multitasker

Normal



WAS



XLN



Eczema – an enigma of WASp deficiency



Eczema in WAS patients???


Cell-trafficking disease
Hyporesponsive cells




cause for development of eczema in WAS Eczema mouse model

animal model

Marisa Baptista




WT
WASP KO




WASp KO mice have reduced epidermal thickening upon Der p 2 challenge

WT




CD3 CD4 CD8


WASp KO




WASp KO mice accumulate dendritic cells and CD8+ T cells in the dermis




WASP-deficient dendritic cells fail to activate CD4+ T cells




WASP-deficient dendritic cells fail to activate CD4+ T cells





WASP-deficient dendritic cells activate CD8+ T cells




WASP-deficient dendritic cells activate CD8+ T cells



Increased expansion of CD8+ T cells over CD4+ T cells in DC-specific WASp KO mice




Increased expansion of CD8+ T cells over CD4+ T cells in DC-specific WASp KO mice




DCs in the wildtype setting

CD8+ DCs




CD8- DCs




10% of spleen DCs

50% of spleen DCs

WASp KO CD8- DCs have increased capacity to cross-present antigen





WASp KO CD8- DCs have increased capacity to cross-present antigen





WASp KO CD8- DCs have decreased capacity to acidify exogenous antigen

Acidification




WASp KO CD8- DCs have decreased capacity to acidify endocytic vesicles


Acidification



CD8+ DCs




CD8- DCs



WT
WASP KO


WASP-deficient CD8- DCs have increased expression of Rac2

CD8+ DC






WASP-deficient CD8- DCs can efficiently recruit Rac2 to their phagosomal membrane

CD8+ DC




Rac2 localization




WASP-deficient CD8- DCs can efficiently recruit Rac2 to their phagosomal membrane

CD8+ DC




Rac2 activation

Total Rac-GTP




Rac2-GTP




WASP-deficient DCs have increased ROS production

CD8+ DC




NADPH activity and ROS production


CD8⁺ CD8+ DCs




ROS production CD8⁺ DC CD8- DC





ROS production CD8- DC





WASP-deficient dendritic cells fail to activate CD4+ T cells



WASP-deficient dendritic cells Induce activation of CD8+ T cells




Deletion of WASP triggers Rac2 activation and increased cross-presentation by dendritic cells




DCs in the wildtype setting

CD8+ DCs



CD8- DCs




10% of spleen DCs


50% of spleen DCs

DCs in WASp deficiency

CD8+ DCs



CD8- DCs




10% of spleen DCs



50% of spleen DCs

Can tumor antigens be routed into the cross-presentation pathway by targeting the actin cytoskeleton?


Wildtype DC



WASp-deficient DC








★ - treated DC



★ Small molecule inhibitor


Can tumor antigens be routed into the cross-presentation pathway by targeting the actin cytoskeleton? – Yes!




■ WT
■ WT + CK666

Oliveira and Westerberg, unpublished


Adaptive immunity - Antigen presentation



Adaptive immunity - Antigen presentation




Checkpoint therapy (anti-CTLA4 and anti-PD-1 Ab): "Releasing the breaks"




Lawrence et al, *Nature* 2013
Palucka and Banchereau, *Immunity* 2013
Sharma and Allison *Cell* 2015, *Science* 2015

Checkpoint therapy – survival in Melanoma



Sharma and Allison, Cell 2015


Therapeutic vaccine candidates



Dendritic cell

- Nucleic acid (DNA, RNA)
- Synthetic peptides (short long)
- Recombinant proteins (antigen, antigens fused with anti-DC Ab)
- Tumor cells (Genetically modified and/or killed)
- Viral vectors (oncolytic, antigen cassettes)
- Bacteria

Therapeutic vaccine candidates



Desired properties of CD8+ T cells

High TCR affinity, T cell avidity


High granzyme, perforin

High proliferation potential

Express chemokine receptors

Express integrins CD49a, CD103

Therapeutic vaccine candidates



Hurdles to overcome

T cell intrinsic regulators: CTLA4, PD-1, LAG-3, TIM-3, 2B4


T cell extrinsic regulators: suppressor cells (Treg cells, MDSC, macrophage)
soluble factors (IL-10, TGF- β , IL-13)

tumor derived suppressive surface factors (B7 family, IDO, ILT, HLA-E)

Access to tumor site: loss of tumor antigen and MHC class I, lack of chemokines,
adhesion molecules, tumor vascularization


Neoantigen: A Long March toward Cancer Immunotherapy

Somatic mutations in cancer give rise to neoantigens



Lawrence et al, Nature 2013

Design of mutation-specific TCR gene therapy for the clinic





Conundrum in Immunology:

How can an immune system fail to respond to
non-self pathogens while **reacting vigorously to**
auto-antigens and allergens?

Conundrum in Immunology:

How can an immune system fail to respond to non-self pathogens while **reacting vigorously to auto-antigens and allergens?**





Harvard Medical School
Scott Snapper
Luigi Notarangelo
Jolan Walter

Maryland University
Wenxia Song

University College London
Adrian Thrasher
Siobhan Burns

Baylor College of Medicine
Jordan Orange

Leuven University
Peter Vandenberghe

Karolinska Institutet
Mikael Karlsson
John Andersson
Susanne Nylén
Liv Eidsmo
Fredrik Wermeling
Piergiorgio Percipalle
Klas Kärre



Karolinska
Institutet



WASPSTINGS
Network 